With FDA nod, AstraZeneca's FluMist becomes first self-administered flu vaccine
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on AstraZeneca's influenza vaccine FluMist for self-administration by adults up to 49 years old and for administration by a parent or caregiver in kids between the ages of 2 and 17.
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...
AstraZeneca Plc has strong compliance policies in China and is working closely with authorities following the detention of ...
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback